Biopharmas raising money in public or private financings, including: 858 Therapeutics, Apimeds, Inscobee, Mirai, Wave Life Sciences.

Med-tech firms raising money in public or private financings, including: Eyenovia, Venus Concept.

Biopharmas raising money in public or private financings, including: Alpha Cognition, Bioage Labs.

Med-tech firms raising money in public or private financings, including: Mdxhealth, Mendaera, Qure.ai.

In one of the largest private rounds raised by an Italian biotech, Genespire Srl has closed a €46.6 million (US$51.88 million) series B, enabling it to lay the ground for a phase I/II clinical trial of its lead program, GENE-202, and to further develop its proprietary lentiviral vectors. The vectors are designed to be applicable to a range of liver-related metabolic disorders and, as its first indication, the company intends to treat methylmalonic acidemia, a serious genetic condition that results in impaired metabolism of certain amino acids and lipids.

One of Australia’s newest biotech investment funds is set to triple investments on the back of its success and strong investor demand. The three-year old Merchant Biotech Fund (MBF) invested in several high growth ASX-listed and private life sciences companies and finished the past financial year up more than 70%. It is up 10% for the current financial year, Portfolio Manager Reece O'Connell told BioWorld.

Biopharmas raising money in public or private financings, including: Aptadir, Biovaxys, Biovie, Immutep, IMV, Lift Biosciences, Longbio Pharma, Verimmune.